BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL
    2.
    发明申请
    BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL 有权
    作为用于增加HDL-C,低LDL-C和较低胆固醇的PPAR-DELTA激动剂的苯扎维林氧化胆酸衍生物

    公开(公告)号:US20100120748A1

    公开(公告)日:2010-05-13

    申请号:US12689335

    申请日:2010-01-19

    摘要: The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

    摘要翻译: 本发明涉及用作PPAR激动剂的式(I)化合物。 治疗一种或多种病症的药物组合物和方法,包括但不限于糖尿病,肾病,神经病,视网膜病,多囊卵巢综合征,高血压,缺血,中风,肠易激综合征,炎症,白内障,心血管疾病,代谢综合症, 还描述了使用本发明化合物的超低密度脂蛋白胆固醇血症,血脂异常(包括高甘油三酯血症,高胆固醇血症,混合性高脂血症和低HDL-胆固醇血症),动脉粥样硬化,肥胖症和与脂质代谢和能量内环境平衡并发症相关的其它障碍。

    Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol
    3.
    发明授权
    Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol 有权
    用于增加HDL-C,较低LDL-C和较低胆固醇的苯并氮杂氧 - 乙酸衍生物作为PPAR-δ激动剂

    公开(公告)号:US08633184B2

    公开(公告)日:2014-01-21

    申请号:US12689335

    申请日:2010-01-19

    摘要: The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

    摘要翻译: 本发明涉及用作PPAR激动剂的式(I)化合物。 治疗一种或多种病症的药物组合物和方法,包括但不限于糖尿病,肾病,神经病,视网膜病,多囊卵巢综合征,高血压,缺血,中风,肠易激综合征,炎症,白内障,心血管疾病,代谢综合症, 还描述了使用本发明化合物的超低密度脂蛋白胆固醇血症,血脂异常(包括高甘油三酯血症,高胆固醇血症,混合性高脂血症和低HDL-胆固醇血症),动脉粥样硬化,肥胖症和与脂质代谢和能量内环境平衡并发症相关的其它障碍。

    Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol
    4.
    发明授权
    Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol 有权
    用于增加HDL-C,较低LDL-C和较低胆固醇的苯并氮杂氧 - 乙酸衍生物作为PPAR-δ激动剂

    公开(公告)号:US07678786B2

    公开(公告)日:2010-03-16

    申请号:US11736221

    申请日:2007-04-17

    摘要: The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

    摘要翻译: 本发明涉及用作PPAR激动剂的式(I)化合物。 治疗一种或多种病症的药物组合物和方法,包括但不限于糖尿病,肾病,神经病,视网膜病,多囊卵巢综合征,高血压,缺血,中风,肠易激综合征,炎症,白内障,心血管疾病,代谢综合症, 还描述了使用本发明化合物的超低密度脂蛋白胆固醇血症,血脂异常(包括高甘油三酯血症,高胆固醇血症,混合性高脂血症和低HDL-胆固醇血症),动脉粥样硬化,肥胖症和与脂质代谢和能量内环境平衡并发症相关的其它障碍。